Equities Analysts Offer Predictions for TENX FY2024 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Roth Capital boosted their FY2024 EPS estimates for shares of Tenax Therapeutics in a report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff now anticipates that the specialty pharmaceutical company will post earnings per share of ($1.16) for the year, up from their previous forecast of ($6.01). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $1.82 EPS and FY2028 earnings at $3.08 EPS.

Several other research analysts also recently weighed in on TENX. StockNews.com initiated coverage on Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating for the company. Leerink Partnrs upgraded Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. Leerink Partners assumed coverage on Tenax Therapeutics in a report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price target for the company. William Blair assumed coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock. Finally, Guggenheim assumed coverage on shares of Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 price target for the company. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Tenax Therapeutics has an average rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Price Performance

Shares of TENX opened at $4.86 on Monday. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $33.44. The company’s 50 day simple moving average is $4.04 and its 200 day simple moving average is $3.71.

Hedge Funds Weigh In On Tenax Therapeutics

A number of large investors have recently modified their holdings of TENX. Sphera Funds Management LTD. purchased a new stake in shares of Tenax Therapeutics during the 3rd quarter worth about $101,000. Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics during the third quarter worth approximately $173,000. Finally, Vestal Point Capital LP purchased a new stake in Tenax Therapeutics during the third quarter worth approximately $288,000. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.